Skip to main content
Contact us

Leading CDMO Companies in India

Your Trusted Partners in India for Contract Manufacturing

Applied Filters:APAC×Clear All
Showing 28 facilities
SENN India | Non-GMP Plant | Hyderabad, India
India

SENN India | Non-GMP Plant | Hyderabad, India

Senn Chemicals

Large scale non GMP manufacturing site for peptide intermediates, organic synthesis, LPPS operations and scale up production.

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: APAC

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: COSMETICS, CHEMICAL-SYNTHETIC, SERVICES, PARTICLE ENGINEERING

SENN India | R&D Lab | Hyderabad, India
India

SENN India | R&D Lab | Hyderabad, India

Senn Chemicals

R&D centre for peptide and organic chemistry with SPPS, purification, lyophilisation, analytics and particle engineering support.

SERVICES: Logistics, Development services, Analytical / QC services, Quality Assurance services, Packaging

REGION: APAC

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC, PARTICLE ENGINEERING

BATCH SIZE: Small

Viswa Laboratories Pvt Ltd
India

Viswa Laboratories Pvt Ltd

Viswa Laboratories Private Limited

CRAMS/CDMO, APIs, Intermediates and specialty chemicals.

MARKETS: EMA (EU), NMPA (China), ANVISA (Brazil), Russian Health Authorities, CDSCO (India)

REGION: APAC

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

BSL (Biological Safety Level): 1, 2

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (J) Antiinfectives for systemic use, (M) Musculoskeletal system, (R) Respiratory system

CONTROLLED SUBSTANCES: Lowest potential for abuse, Low potential for abuse, Lower potential for abuse

OEB (Occupational Exposure Banding): 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

COMPLIANCE: World Health Organization (GMP / HACCP)

Hikal Ltd | Bangalore, India
India

Hikal Ltd | Bangalore, India

Hikal Ltd.

cGMP Process Development, Scale-up and Manufacturing of Small Molecule APIs, NMEs and Intermediates from grams to tones.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), COFEPRIS, Halal Research Council, ECOVADIS, TGA (Australia GMP), EMA (EU GMP)

BATCH SIZE: Large, Small, Medium

CATEGORY / PRODUCT: COSMETICS, NUTRACEUTICALS, CHEMICAL-SYNTHETIC, SERVICES

USE: Human, Veterinary

SERVICES: Development services, Manufacturing services

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (V06) Nutrients

Limited view

CHEMICAL-SYNTHETIC manufacturing site

MAI network supplier

An API and Interemediate manufacturer having global certifications.

Location available after registration

Limited view

BIOLOGICS manufacturing site

MAI network supplier

GMP-compliant biologics manufacturing facility specializing in recombinant enzymes and proteins.

Location available after registration

Limited view

COSMETICS manufacturing site

MAI network supplier

Small molecule drug substance development and manufacturing site.

Location available after registration

Suggested Results

These facilities match your main criteria but not every optional filter — including other countries in the same region.

Adragos Pharma | Kawagoe
Japan

Adragos Pharma | Kawagoe

Adragos Pharma

Our facility provides best-in-class manufacturing of tablets and ampoules.

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), MHRA (UK), SFDA (Saudi Arabia), MFDS (South Korea), EDE (UAE), CDSCO (India), TGA (Australia)

COMPLIANCE: FDA (cGMP), PMDA/MHLW (Japan GMP), EMA (EU GMP)

USE: Human

BATCH SIZE: Large

SERVICES: Logistics, Analytical / QC services, Packaging, Regulatory services, Quality Assurance services, Manufacturing services

CONTROLLED SUBSTANCES: Lowest potential for abuse, Lower potential for abuse, High potential for abuse & medical use, Low potential for abuse

OEB (Occupational Exposure Banding): 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 2 (PDE = 1,000 - 10,000 µg/day)

CATEGORY / PRODUCT: FDF / DRUG PRODUCTS, SERVICES

REGION: APAC

Pharmaron API Commercial Synthesis Shaoxing (China)
China

Pharmaron API Commercial Synthesis Shaoxing (China)

Pharmaron

Commercial API Small Molecules /Peptides Synthesis.

THERAPEUTIC AREAS OF EXPERTISE (ATC): (V04) Diagnostic agents, (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: NMPA (China), FDA (USA)

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, NMPA (China GMP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services

ProBio CDMO | Biologics Platform
China

ProBio CDMO | Biologics Platform

Probio

Global GCT and biologics CDMO, accelerating your pipeline from gene to commercial market.

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), EMA (EU GMP)

BATCH SIZE: Large, Small, Medium

USE: Human

CATEGORY / PRODUCT: BIOLOGICS

Apeloa Pharmaceutical Co., Ltd.
China

Apeloa Pharmaceutical Co., Ltd.

Apeloa Pharmaceutical Co., Ltd

Apeloa CDMO provides world-class discovery, development, and manufacturing services for APIs, Intermediates, and RSMs.

OEB (Occupational Exposure Banding): 5 / HPAPI (PDE < 10 µg/day), 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day)

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia)

REGION: APAC

COMPLIANCE: FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ECOVADIS, NMPA (China GMP), EMA (EU GMP), World Health Organization (GMP / HACCP)

BATCH SIZE: Large, Small, Medium

USE: Human, Veterinary

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

SERVICES: Development services, Manufacturing services, Analytical / QC services, Regulatory services, Packaging

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site
China

Sichuan Huiyu Pharmaceuticals Co., Ltd. - API Manufacturing Site

Seacross Pharmaceutical Co Ltd

As one of three core sites, alongside the R&D center and formulation plant, our API manufacturing facility plays a vital role in the integrated supply chain.

CONTROLLED SUBSTANCES: High potential for abuse & medical use, Lowest potential for abuse, Low potential for abuse, High potential for abuse & no medical use, Lower potential for abuse

MARKETS: EMA (EU), PMDA (Japan), NMPA (China), FDA (USA), Health Canada (Canada), ANVISA (Brazil), ISP (Chile), MSPAS (Guatemala), COFEPRIS (Mexico), DIGEMID (Peru), Russian Health Authorities, MHRA (UK), ANMAT (Argentina), INVIMA (Colombia), SFDA (Saudi Arabia), MFDS (South Korea), Turkish Health Authorities, EDE (UAE), CDSCO (India), TGA (Australia), Rest of World

SERVICES: Logistics, Development services, Manufacturing services, Analytical / QC services, Quality Assurance services, Regulatory services, Packaging

REGION: APAC

COMPLIANCE: DIGEMID, BRCGS, FDA (cGMP), ISO, PMDA/MHLW (Japan GMP), ANVISA (Brazil B-GMP), MSPAS, COFEPRIS, Roszdravnadzor (Russia GMP), IFS, Halal Research Council, ECOVADIS, TGA (Australia GMP), TITCK (Turkish Health Authorities), UAE Ministry of Health & Prevention, SFDA (Saudi Food & Drug Authority), INVIMA, ISP (Chile BPM), French Service-Public (CIR), NMPA (China GMP), ANMAT (Argentina nueva GMP), EMA (EU GMP), Health Canada (Canada GMP), World Health Organization (GMP / HACCP), MHRA (UK GMP), MFDS/KFDA (Republic of Korea GMP), SQF (Safe Quality Food), NSF

BATCH SIZE: Large, Small, Medium

USE: Human

BSL (Biological Safety Level): 1, 2, 3, 4

CATEGORY / PRODUCT: CHEMICAL-SYNTHETIC

THERAPEUTIC AREAS OF EXPERTISE (ATC): (C) Cardiovascular system, (D) Dermatologicals, (H) Systemic hormonal preparations excl. sex hormones and insulins, (J) Antiinfectives for systemic use, (L) Antineoplastic and immunomodulating agents, (M) Musculoskeletal system, (N) Nervous system, (P) Antiparasitic products, insecticides and repellents, (R) Respiratory system, (S) Sensory organs, (V01) Allergens, (V06) Nutrients, (V09-10) Radiopharmaceuticals, (B) Blood and blood forming organs, (A) Digestive tract and metabolism, (G) Genito urinary system and sex hormones, (V04) Diagnostic agents

OEB (Occupational Exposure Banding): 4 / HPAPI (PDE = 10 - 100 µg/day), 2 (PDE = 1,000 - 10,000 µg/day), 3 (PDE = 100 - 1,000 µg/day), 1 / low-hazard (PDE > 10,000 µg/day), 5 / HPAPI (PDE < 10 µg/day)

More facilities on the network

Register to unlock the full catalog with contact details and locations.

+21 more facilities

Create free account

India is a rapidly growing hub for pharmaceutical development and manufacturing, attracting global attention for its robust infrastructure and cost-efficient capabilities. CDMO companies in India are well-integrated into global supply chains, offering expertise in clinical trial supply, commercial manufacturing, and regulatory support aligned with FDA, EMA, and global standards.

From agile biotech innovators to multinational pharma companies, organizations partner with CDMOs in India for their technical expertise, regulatory compliance, and ability to scale rapidly across global markets.

Why Choose CDMOs in India?

India offers a unique value proposition: a skilled workforce, advanced pharmaceutical infrastructure, and strong regulatory track record with global health authorities. CDMOs in India are supported by government initiatives like PLI schemes and benefit from a cost-effective manufacturing environment and extensive global export network.

With proven experience in complex molecules, including high-potency APIs, biologics, and niche formulations, CDMOs in India are trusted partners for global drug development and commercialization programs.

Key Services Offered by CDMO Companies in India

  • Clinical Supply Manufacturing: Phase I–III production with accelerated timelines and global distribution capabilities.
  • Regulatory & Submission Support: Expertise in US FDA, EMA, DCGI, and ROW submissions, including IND, ANDA, and NDA documentation.
  • High-Potency & Specialty Manufacturing: Capabilities in oncology, hormones, sterile injectables, and complex formulations.
  • GMP Packaging & Serialization: Regulatory-compliant labeling and packaging with cold chain and export logistics.
  • Tech Transfer & Commercial Manufacturing: Seamless scale-up from lab to launch with validated, commercial-ready processes.

Advantages of Partnering with CDMOs in India

  • Global Regulatory Compliance: US FDA, EMA, MHRA, and WHO-GMP approved facilities with strong audit history.
  • Competitive Cost Structure: Significant cost savings without compromising on quality or speed.
  • Skilled Scientific Workforce: Access to highly qualified professionals in pharma R&D, manufacturing, and regulatory affairs.
  • Scalable Infrastructure: Large-volume production, flexible batch sizes, and dedicated high-containment suites.
  • Proven Global Track Record: Long-standing partnerships with top-20 global pharma and biotech companies.

CDMO Companies in India

Some of the leading CDMO companies in India include:

  • Shilpa Biologicals: A full-service CDMO in India offering end-to-end development and manufacturing for biologics and complex generics. [See CDMO profile]
  • Viswa Laboratories: Specializes in APIs, high-potency compounds, sterile products, and integrated drug development. [See CDMO profile]
  • SWISS Parenterals: Established in 1999, this Indian CDMO manufactures sterile products including ophthalmic drops, pre-filled syringes, eye ointments, ampoules, and inhalation solutions. [See CDMO profile]
  • 3xper: Your trusted CDMO/CRO partner providing tailored support from discovery to commercialization. [See CDMO profile]
  • Syfine Drugs: Based in Hyderabad, Syfine Drugs is an innovative pharmaceutical company engaged in high-quality manufacturing for global markets. [See CDMO profile]
  • Kemwell Biopharma Pvt Ltd: Biologics focused Contract Development and Manufacturing (CDMO) company providing services to global biopharmaceutical organisations. [See CDMO profile]
  • Hikal Ltd | Bangalore, India: cGMP process development, scale-up and manufacturing of small molecule APIs, NMEs and intermediates, from gram to kilogram and tonne scale, supporting projects from laboratory stage through commercial launch. [See CDMO profile]

Related Information

Leading CDMO Companies in APAC

Let MAI CDMO Network Help You Find the Right Indian CDMO Partner

Navigating the Indian CDMO ecosystem requires local expertise and trusted networks. MAI CDMO helps you identify the most suitable CDMO companies in India—with the right capabilities, certifications, and technical know-how to accelerate your program.

From early clinical batches to global commercial supply, our personalized matchmaking ensures you find a CDMO in India that fits your goals, timelines, and quality expectations.

Contact MAI CDMO Network today and connect with a trusted CDMO in India to bring your product from lab to launch.